Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / MAGEA6



This biomarker is also known as:
  • cancer/testis antigen family 1, member 6,
  • MAGE-6 antigen,
  • CT1.6,
  • MAGE-3b,
  • Cancer/testis antigen 1.6,
  • cancer/testis antigen 1.6,
  • melanoma antigen family A, 6,
  • MAGE6,
  • MAGE3B antigen,
  • MAGE3B,
  • melanoma-associated antigen 6,

View in BioMuta


The members of the MAGEA protein family display 50-80% sequence identity among their members. MAGEA proteins are thought to play a role in tumor transformation or aspects of tumor progression. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. Alternative splicing results in multiple transcript variants.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

MAGEA6 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.